Insulin Therapy and Lipoproteins' Profile in Type 1 Diabetes.

Launched by POZNAN UNIVERSITY OF MEDICAL SCIENCES · Nov 29, 2014

Keywords

ClinConnect Summary

This clinical trial is studying how insulin therapy affects the levels and types of fats in the blood, known as lipoproteins, in people who have just been diagnosed with type 1 diabetes. The researchers want to understand how insulin impacts HDL, a type of good cholesterol, and to examine other factors that might influence these changes. They will follow at least 100 participants over 5 to 10 years, taking measurements at the time of diagnosis and then again after 3 weeks, 6 months, and 12 months of starting insulin treatment. Participants will also have regular check-ups every three months to monitor their metabolic health.

To be eligible for this study, participants need to be newly diagnosed with type 1 diabetes and start insulin therapy. They must also be in good health without any other medical conditions or medications besides insulin. Throughout the study, participants can expect to undergo various tests to measure different aspects of their blood fat levels and overall health. The findings from this research could help improve diabetes treatment and potentially enhance the quality and length of life for individuals living with type 1 diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • New onset type 1 diabetes and treatment with insulin.
• • Written consent to participate in the study.
• • There are no other medical conditions, and with no other additional drugs beyond insulin
• Exclusion Criteria:
• • any other medical conditions, and any other additional drugs beyond insulin